Neurogene (NGNE) 8-K Entry into a Material Definitive Agreement

Exhibit 10.3

AMENDMENT No. 1

to the

FACILITY USE AGREEMENT

This Amendment No. 1 to the Facility Use Agreement (the “Agreement”) (hereinafter referred to as the “Amendment”) is made as of April 17, 2019 (the “Effective Date”), by and between the INSTITUTE FOR SYSTEMS BIOLOGY (“ISB”), a Washingtonnon-profit corporation, and NEOLEUKIN (“User”), a Delaware Corporation. ISB and the Company are collectively referred to as the “Parties” and individually as a “Party”.

RECITALS

WHEREAS, The User and ISB are parties to a certain Facility Use Agreement (the “Agreement”) dated November December 4, 2018;

WHEREAS, The User and ISB desire to amend the Agreement to adjust the rentable square feet identified in the Agreement, as more particularly described in this Amendment No. 1. All other provisions of the Agreement remain in full force and effect; and

NOW, THEREFORE, the Parties hereby agree to amend the Agreement as follows:

1. In paragraph 1.a., line one, deletetwo thousand thirty (2,030)in its entirety and insertthree thousand five hundred (3,500);

2. Delete Exhibit C “Description of Space” in its entirety and replace with Exhibit C included in this Amendment.

INSTITUTE FOR SYSTEMS BIOLOGY   By: /s/ Becky Johnson   Title: Director of Facilities & Operations   Date: April 17, 2019 NEOLEUKIN   By: /s/ Jonathan G. Drachman   Title: CEO, Neoleukin Therapeutics   Date: April 17, 2019

EXHIBIT C

DESCRIPTION OF SPACE

Office space in the Southeast corner of the 4^th floor (L4) and lab space in the South end of the 3^rd floor (L3) as depicted below.

L4 Office Space

L3 Office Space

Note: Partial end cap,-80 strorage and space in room 389 are not depicted in this map.